Diet and exercise rival heart drugs in pooled data on 312,645 people

Cardiovascular disease remains the leading cause of death globally, and much of the risk traces back to modifiable factors: what people eat, how much they move and whether they smoke. Medication for blood pressure, cholesterol and related risks is well established, but a basic question has never been clearly quantified: how does changing behaviour compare with taking drugs when it comes to preventing heart attacks, strokes and death? Patients and clinicians make trade-offs between these approaches every day, usually without direct evidence on their relative worth. This review set out to put numbers on that comparison in middle-aged and older adults.

The authors searched PubMed, Embase and Cochrane CENTRAL from inception to June 2025 for studies of lifestyle modification and pharmacologic therapy in cardiovascular prevention. They included 21 randomised controlled trials and 11 prospective cohort studies, totalling 312,645 participants. The outcomes of interest were major adverse cardiovascular events, all-cause mortality, cardiovascular mortality and stroke incidence. Pooled risk ratios were calculated using random-effects models, with sensitivity analyses and checks for publication bias.

Lifestyle interventions were associated with significantly lower risks across every outcome examined: a risk ratio of 0.85 for major adverse cardiovascular events, 0.88 for all-cause mortality, 0.84 for cardiovascular mortality and 0.82 for stroke. Programmes that combined diet and exercise showed the greatest benefit, with a risk ratio of 0.80. The results held up across sensitivity analyses and showed no evidence of publication bias. On this basis the authors conclude that lifestyle modification provides cardiovascular protection comparable to or greater than pharmacologic therapy.

The individual ingredients here are not new; decades of work link diet, exercise and smoking cessation to better cardiovascular outcomes. What this analysis adds is the direct framing against medication, and its conclusion pushes back on the assumption that drugs are the serious intervention while lifestyle is the garnish. The mix of randomised trials with studies that merely followed people is the key limitation, since the two designs carry different risks of bias, and the comparison with drug therapy is drawn across studies rather than within them. Head-to-head trials would be needed to settle the question properly.

This is a reason to treat diet and exercise as first-order tools for heart health rather than an optional extra alongside prescriptions. The pattern in the data favoured combined programmes, movement plus better eating together, over either alone. None of this suggests that anyone should stop or avoid prescribed medication; the authors themselves describe drugs as valuable and complementary. The takeaway is about how much weight behaviour deserves in the overall picture, not a choice between the two.